A method of growing human cells from tissue removed from a patient’s gastrointestinal (GI) tract eventually may help scientists develop tailor-made therapies for inflammatory bowel disease and other GI conditions.
Reporting online recently in the journal Gut, researchers at Washington University School of Medicine in St. Louis said they have made cell lines from individual patients in as little as two weeks. They have created more than 65 such cell lines using tissue from 47 patients who had routine endoscopic screening procedures, such as colonoscopies. A cell line is a population of cells in culture with the same genetic makeup.
The scientists said the cell lines can help them understand the underlying problems in the GI tracts of individual patients and be used to test new treatments.
“While it has been technically possible to isolate intestinal epithelial stem cells from patients, it has been challenging to use the material in ways that would benefit them on an individual basis,” said co-senior investigator Thaddeus S. Stappenbeck, MD, PhD, a professor of pathology and immunology. “This study advances the field in that we have developed new methods that allow for the rapid expansion of intestinal epithelial stem cells in culture. That breaks a bottleneck and allows us to develop new ways to test drug and environmental interactions in specific patients.”
To grow the human cells, the researchers adapted a system used to grow intestinal epithelial stem cells in mice. In the GI tract, epithelial cells line the inner surface of the esophagus, stomach and intestines.
“An additional important feature of this system is that we can isolate stem cell lines from intestinal biopsies,” said first author Kelli L. VanDussen, PhD, a postdoctoral fellow in Stappenbeck’s laboratory. “These biopsies are very small tissue fragments that are routinely collected by a gastroenterologist during endoscopy procedures. We have refined this technique, so we have nearly 100 percent success in creating cell lines from individual patient biopsies.”
The researchers developed an experimental system that created high levels of critical factors to isolate and expand intestinal epithelial stem cells, including a signaling protein called Wnt and a related protein called R-spondin, which enhances the Wnt signal. They also exposed the cells to a protein called Noggin, which prevented the cells from differentiating into other cell types that live in the GI tract.
After growing the intestinal cell lines, the investigators collaborated with Phillip I. Tarr, MD, the Melvin E. Carnahan Professor of Pediatrics and director of the Division of Pediatric Gastroenterology and Nutrition, to conduct experiments and see how the cells interacted with bacterial pathogens like E. coli.
This showed that pathogenic strains of E. coli attached to intestinal epithelial cells. That attachment is thought to be the critical step in stimulating disease. The investigators said the experimental system they created should lead to new methods to uncover therapies for treating bacterial infections of the intestine.
“In the past, the only really robust method for studying GI epithelial cells was to use cancer cell lines,” said co-senior investigator Matthew A. Ciorba, MD, a gastroenterologist and assistant professor of medicine. “However, cancer cells behave differently than the noncancerous GI epithelium, which is affected in patients with conditions such as inflammatory bowel disease. This technique now allows us to study cells identical to the ones that live in a patient’s GI tract. Plus, we can grow the cell lines quickly enough that it should be possible to develop a personalized approach to understanding a patient’s disease and to tailor treatment based on a patient’s underlying problem.”
The researchers said the new technique is relatively simple and inexpensive and could easily be adapted for use in other laboratories.
“You can grow these cells, differentiate them and then test various therapies using these cells,” Stappenbeck explained. “If we want to learn whether particular patients have a susceptibility to certain types of infections, we can test that. We’re very excited about this going forward because we’re entering new territory. We’ve never been able to do this before.”
Looking ahead, the researchers believe these cell lines will be useful in testing for new drug targets, for vaccine development and to better understand how these human cells interact with the beneficial and the harmful microbes that also live in the gut.
This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), the Mucosal Immunology Studies Team Translational Pilot Project and Young Investigator Pilot Award, and the Crohn’s and Colitis Foundation of America. NIH grant numbers DK071619, DK089016, DK100737, DK90251, P30 DK052574, AI095550 and T32 AI007163.
VanDussen KL, Marinshaw JM, Shaikh N, Miyoshi H, Moon C, Tarr PI, Ciorba MA, Stappenbeck TS. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut, published online July 9, 2014. gutjnl-2013-306651. doi: 10.1136/gutjnl-2013-306651.
Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.